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g.2013.0Abstract Post-operative nausea and vomiting is the most annoying and at the same time a danger-
ous side effect of general anaesthesia. Ondansetron is a routinely used anti emetic drug which is
being administered by the trial and error principle. Though it did revolutionized the management
of this condition but by and large failed to completely eliminate the problem. Recently an important
factor possibly elucidating this failure is said to be the differing expression of genes controlling pro-
teins that are involved in transport and receptors related to this drug. Quite surprisingly these trans-
porter and receptor pathways have been found to be polymorphic and at the same time shown to be
related to efﬁcacy of the drug. The differentiation between those responding to treatment and those
not responding may pave a way to individualize treatment for emesis to a greater extent. This review
highlights the pharmacogenetics related to this commonly used anti-emetic drug in anaesthesia. It is
visualized as a promising way to achieve the target of individualized therapy. It seems obvious that
pharmacogenetics will become an important ﬁeld of anaesthesia research in the future.
 2013 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.Contents
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A strong association of post-operative nausea and vomiting
exists with general anaesthesia ever since the ether and chloro-
form times. Those were the times when the incidence of this
was around 70–80%. With the current advances in anaesthesia
practices, the average incidence has come down by 50% how-
ever in high risk groups it still remains up to 80% [1]. A survey
was conducted by Macario et al. in 1999 where they found it to
be the most common, objectionable and disturbing effect of
general anaesthesia [2]. More recently several authors identi-
ﬁed it as the ‘‘big little problem’’ [3,4] due to the undesirable
outcomes posed by it. The researchers have designated the
occurrence of post-operative nausea and vomiting to ‘‘early’’
when it is occurring within the ﬁrst two hours after surgery,
and when the similar complaints extend to the ﬁrst post-oper-
ative day then they call it the ‘‘delayed’’ post-operative nausea
and vomiting [5]. There are three stages of post-operative nau-
sea and vomiting usually occurring within 24 h of surgery and
these are nausea, retching and vomiting. Nausea is a subjective
feeling in which there is an urge to vomit. Vomiting on the
other hand is when the contents of stomach are forcefully
thrown out of stomach through the mouth [6]. Retching pre-
cedes vomiting and is somewhat in between the two. It is the
result of muscular movement of the abdomen that results in
a non-productive outcome as it occurs when the stomach is
empty [7]. Retching and vomiting can be quantiﬁed and are re-
garded to be objective as compared to nausea which is a sub-
jective feeling.
The consequences of post-operative nausea and vomiting
are far more than what one can appreciate, affecting patients
in many ways. Usually it is said that among the various effects
produced the prominent ones are physical, metabolic, psycho-
logical and economic. The complications related to the patient
include the distress and the discomfort to the patient along
with disruption of the wound with delayed healing and an
overall bad surgical outcome. These all contribute to the
post-operative morbidity creating an immense challenge to
the surgical team as well as the operation theatre trained per-
sonnel. Moreover there is a signiﬁcant burden on the economy
of the country as the health care costs are increased exten-
sively. The contributing factors to this remain the increased
stay of the patients in the wards creating delay in discharge,
postponement in resuming daily works and sometimes even
readmissions become mandatory in the case of unpredictable
complications.
Post-operative nausea and vomiting is believed to be a mul-
tifactorial problem. There is a long list of risk factors but only
few appear to be clearly established. Among these are the fe-
male sex, any previous history of motion sickness or post-oper-
ative nausea and vomiting and the use of volatile anaesthetics,
nitrous oxide and opioids in surgery. They all have proved
from time to time to be the autonomous risk factors contribut-ing to it in various settings. In spite of a large amount of re-
search on the identiﬁcation of risk factors and best possible
treatments available, the data continue to reveal that in the
post-operative rooms 20–30% of the patients experience
post-operative nausea and vomiting [8]. The key cause of this
treatment failure is attributed to the multifactorial genesis of
post-operative nausea and vomiting [9]. Throughout the world
a lot has been done till date to counter this annoying distur-
bance. Researchers have continued to focus on ways to prevent
or treat it. Immense amount of resources, money and zealous
efforts spent so far however failed to bring up a single simple
solution [10].
Recently with new developments in science the pharmaco-
genetics is emerging as an interesting area of medical study.
The genetic makeup is said to affect the response to different
drugs. Thus the focus of researchers has now shifted to the
genetic component likely to be playing an important role
in post-operative nausea and vomiting. They assume that it
may be responsible for treatment failure in some individuals
leading to inter individual variations. The question still re-
mains unanswered and demands further studies to establish
a role of genetics in the management of post-operative nau-
sea and vomiting. Kranke and colleagues (2009) strongly be-
lieved that post-operative nausea and vomiting should not be
considered as the ‘‘big little problem’’, rather it should be
viewed as a ‘‘big little opportunity’’ [8]. We are looking at
this in the similar way hoping that any work in this regard
will represent one of the many efforts towards a complete
understanding of pharmacogenetics of post-operative nausea
and vomiting.
2. Treatments options for post-operative nausea and vomiting
The treatment protocols for the control of post-operative nau-
sea and vomiting can only be designed if there is complete
know how of the risk factors accountable for post-operative
nausea and vomiting. Up till now several pharmacological
agents have come up for the management of this condition.
These drugs are by and large grouped according to the type
of receptor at which they act, usually as an antagonist. The
receptors present in the vomiting centres include serotonin,
dopamine, histamine and muscarinic receptors. The traditional
antiemetic medications directed against these receptors are
antihistamines, anticholinergics, and dopamine receptor antag-
onists. And the newer and recent introduction to this category
is the 5-hydroxytryptamine-3 receptor antagonists (5-
HT3RAs) and the neurokinin receptor antagonists. However
so far none of these drug classes are absolute in the suppres-
sion of post-operative nausea and vomiting and has just pro-
jected the image of an illusion as far as adequate control or
elimination of PONV is concerned. In spite of all the strategies
available, the problem of post-operative nausea and vomiting
exists to the same extent [11].
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5-HT3RAs came into the markets for the treatment of chemo-
therapy induced nausea and vomiting in the early 1990s. Lately
they are now also used for the prevention and treatment of
post-operative nausea and vomiting [12] and they have made
such a strong place in the patient’s treatment plan alongside
drugs for anaesthesia that they are regarded as the ‘‘gold stan-
dard’’ in this regard. The reason for this popularity lies in the
fact that over the course of time they have proved to be far
more effective and safer than the traditional antiemetic drugs.
They are devoid of the side effects that the other commonly
used anti emetics possess. They thus have transformed post-
operative nausea and vomiting and chemotherapy induced
nausea and vomiting treatment to some extent and have pro-
vided some relief to physicians, oncologists and
anaesthesiologists.
5-HT3RAs include ondansetron, tropisetron, granisetron
and dolasetron. All these antagonists have similar chemical
structures to serotonin. They share similar efﬁcacy and ﬁne
acceptability at equipotent doses, however slight differences
exists in the side effect proﬁles of these. Most of the times when
one has to choose among them, the decision depends basically
upon the cost concerns, the safety of the drug, the ease of dos-
ing, and the speciﬁc needs of the patient population in which it
is to be used.
4. Ondansetron
Among all the 5-HT3RAs the ondansetron is the most widely
used drug to prevent post operative nausea and vomiting or
chemotherapy induced nausea and vomiting. It is a carbaz-
alone derivative that is structurally related to serotonin and
possesses speciﬁc 5-HT subtype 3 receptor antagonism. It is as-
sumed that it has no activity at dopaminergic, histaminergic,
adrenergic, and cholinergic receptors. Ondansetron possesses
a favourable drug proﬁle like all 5-HT3RAs. This drug is rec-
ognized by the adenosine triphosphate-binding cassette sub-
family B member 1(ABCB1) drug transporter in the blood
brain barrier which in turn determines the concentration of
drug in the central nervous system. The site of action of ondan-
setron is the 5-HT3 receptors in the central nervous system, the
highest concentration of which are found in the solitary tract
nucleus and the chemoreceptor trigger zone. Ondansetron pro-
duces its antiemetic effects by acting at these sites. Normally
during general anaesthesia serotonin is released from the
enterochromafﬁn cells. This serotonin stimulates the serotonin
receptor which in turn activates the vomiting centre and that is
how emesis is generated [10]. Ondansetron being a serotonin
receptor antagonist binds to these receptors and competitively
blocks them, in this way signals of emesis are prevented from
travelling to the vomiting centre. The binding afﬁnity of
ondansetron for 5-HT3 receptors has a pKi value of 8.07.
The afﬁnity of ondansetron to its receptor plays a vital role
in determining the duration of action and there is as such a les-
ser role of its half-life [13]. It is preferably given through the
intravenous route as this route ensures adequate absorption
and rapid distribution within the body. The half-life approxi-
mately ranges between 3 and 5 h and has duration of action
of 4–48 h. The metabolism of the drug is extensive; initially
there is hydroxylation and then conjugation. There is a de-crease in the clearance of the drug with advancing age which
is very much consistent with the deterioration in hepatic and
renal functions in the elderly [12]. Likewise the hepatic and re-
nal diseases will decrease the clearance of ondansetron.
The dose of ondansetron is variable, largely depending
upon the age of the patient as well as the medical condition
that is being treated. At the same time the dose also depends
upon the other medical conditions that the patient may have.
The clinicians have up till now no choice but to use the trial
and error method to measure the response to ondansetron
and adjust its dose. There is no evidence to compliment the ra-
tional use of drugs in treating emesis.5. Pharmacogenetic issues related to ondansetron
As described earlier there is no complete elimination of post-
operative nausea and vomiting even with the newer drugs, so
is the case with ondansetron. This resistance to ondansetron
is emerging as one of the most serious problems in the treat-
ment of post-operative nausea and vomiting that is likely to
have a complex genetic and acquired basis. It has been of great
concern that patients get the best possible anti emetics during
surgery and yet around 26% still require additional treatment
in the post-operative period and 40% of patients require addi-
tional treatment for post-operative nausea and vomiting even
after discharge from the hospital. Among the patients who
complain of repeated vomiting, the majority are those who
do document a similar family history too. It is now realized
that the genes may be playing a vital role in determining the
individual’s response. Genetic differences inﬂuencing response
to the pharmacotherapy of post-operative nausea and vomit-
ing are under investigation. Candidate genes such as target
receptors, transporters and other molecules important for
pharmacotherapy are under investigation. These genetic varia-
tions are represented as single nucleotide polymorphisms
(SNPs) in the human genome and they vary across the world
population and are present in millions of number. In order
to understand this it is essential to have the basic molecular
concepts.
DNA (deoxyribonucleic acid) encodes the molecular struc-
ture of each protein present in the cell nucleus of humans.
Basically DNA is comprised of a chain which has four types
of nucleotide subunits. Each subunit has a sugar, a phosphate
group, and one of the four bases which are adenine, cytosine,
guanine, and thymine. It exists in the form of a double helix, in
which two individual DNA strands twist around each other. In
this structure guanine pairs with cytosine and adenine pairs
with thymine in accordance with the base pairing rules. Any
variation occurring within the sequence of the base pairs forms
the genetic code. The entire complement of genes in an organ-
ism or cell is called its genome, which may be stored in one or
more chromosomes. Humans have 23 pairs of chromosomes.
A gene is a hereditary coding unit of a living organism com-
posed of a speciﬁc DNA sequence occupying a speciﬁc position
within a chromosome. All genes have a common structure that
includes a 50 untranslated region, exons, introns, and a 30
untranslated region. An allele is any of two or more alternative
forms of a gene occupying the same chromosomal locus. The
most common type of human genetic or allelic variation is
the SNP. Up till now, more than 13 million SNPs have been
recognized. Other types of mutations like insertion, deletion,
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These allelic variations can change the phenotype of an organ-
ism quite appreciably [14]. In recent years, it has been recog-
nized that genetic polymorphisms contribute to immense
alteration in terms of drug responsiveness. The genetic poly-
morphisms form the basis of pharmacogenetics and one of
the primary steps in this regard is to spot polymorphisms in
the candidate genes. The differences in the genetic makeup at
several steps can signiﬁcantly alter the response of a person
to the drug. The several steps in pharmacokinetics and dynam-
ics like absorption, distribution, metabolism, elimination and
concentration of drug at target sites can be altered under their
inﬂuence. A budding list of polymorphisms exists in different
classes of genes encoding these transporters, receptors and tar-
gets, and this has been associated to the effects of drug in hu-
man beings, playing an important role in therapeutic outcome.
The well known variations in drug transporters and drug tar-
get genotype in different geographic regions of the world are
enough to prompt the investigators to determine the frequency
of its genotypes in local population.
6. Variation in genes encoding drug transporters
Drug transporters play a key role in the passage of drugs
across the blood brain barrier thus determining the disposition
of drugs. Similarly the transporter ABCB1 has a role in the
pharmacokinetics of ondansetron which is a substrate for P-
glycoprotein (P-gp) [15]. It is a protein traversing the mem-
brane that plays the role of an efﬂux pump [16]. This function
of ABCB1 apparently is very important as it seems to be pro-
tecting the central nervous system from toxic compounds. On
the other hand, certain drugs are prevented from entering the
central nervous system. Over 50 SNPs in ABCB1 have been
documented, which are said to affect the expression and func-
tion of P-gp [17] which is a member of ABCB1 family [18]. The
two SNPs are of particular signiﬁcance. One is the mutation at
position 3435 in exon 26 (3435C > T) and the second is a
mutation in exon 21 at position 2677 (2677G> T/A). Due
to the presence of association with differences in expression
or function of P-gp, 3435C > T has been extensively studied.
Among various populations, a synonymous SNP,
3435C > T (amino acid position 1145) and a non-synonymous
SNP, 2677G > T/A (amino acid position 893) are the most
common polymorphisms and reported to be in linkage disequi-
librium [19–21]. In addition, these polymorphisms have shown
a high inter-ethnic variability [22–25]. Siddiqui et al. in 2003
demonstrated that the epileptic patients with the TT genotype
at ABCB1 3435 exhibited a better drug response [26]. Two
years later a study conducted in Turkey concluded that the
3435C > T SNP of ABCB1 was associated with the efﬁcacy
of 5-HT3RAs for CINV [27]. Recently Chio et al. in 2010 dem-
onstrated a signiﬁcant association between the ABCB1 gene
polymorphism and the response to ondansetron in post-oper-
ative nausea and vomiting patients. The incidence of post-
operative nausea and vomiting was lower in patients with
2677TT and 3435TT genotypes than other genotypes during
the ﬁrst 2 h after surgery. It is likely that there was a higher
concentration of ondansetron in the central nervous system
in patients with 2677TT and or 3435TT genotype and thus re-
sponded better to ondansetron [28]. Therefore, it is sensible to
hypothesize that the availability of ondansetron across theblood brain barrier could be inﬂuenced by the genetic variance
of this transporter. This in turn affects the antiemetic efﬁcacy
of ondansetron [11].
This large number of SNPs in ABCB1 have been identiﬁed
and reported in populations such as African Americans, Euro-
peans and Asians like the Japanese. However a lot more needs
to be done. It may be possible to target treatment appropri-
ately, if it becomes possible to predict the responsiveness of
post-operative nausea and vomiting to ondansetron. There-
fore, it would be of great interest to determine the SNPs in
ABCB1gene in different populations and to establish the
importance (if any) of the identiﬁed SNPs as potential determi-
nant of altered drug response.
7. Variation in genes encoding drug receptors
The 5-HT3 receptor is an ion channel that is ligand-operated
[29]. It is found on parasympathetic terminals in the gastroin-
testinal tract, the nucleus tractus solitarius and area postrema
of the central nervous system [30]. There are ﬁve different
receptor subunits of the 5-HT3 receptors recognized in humans
up till now: 5-HT3A, B, C, D, and E. A variety of effects are
produced as a result of activation of theses 5-HT3 receptors
such as emesis and behavioural effects including anxiety,
depression and cognitive disorders [31]. 5-HT3RAs speciﬁcally
bind to the 5-HT3A, 5-HT3B receptor complex and so does the
ondansetron and produce its effects. The 5-HT3B subunit has
shown to be the most important for its functionality.
As with the transporters there is also an emerging list of
polymorphisms found in the gene encoding the target site of
ondansetron. The genetic variation in 5HT3B receptor has
markedly affected the individual responsiveness to the drug.
Several studies in Caucasians have shown an association be-
tween polymorphisms in the gene encoding the 5-HT3B recep-
tor and antiemetic response to 5-HT3RAs. A pharmacogenetic
study in German Caucasian patients was performed by Tremb-
lay et al., who were receiving chemotherapy drug regimens. Pa-
tients were given tropisetron or ondansetron prophylactically
for chemotherapy induced nausea and vomiting. It was ob-
served that the patients had the maximum intensity of nausea
and vomiting after chemotherapy if they were homozygous for
the 100–102AGG deletion variant of the 5-HT3B receptor
gene, whereas the patients had less of these complaints who
were having the wild type. This study included 242 patients
only and thus the data were required to be conﬁrmed with
much larger sample sizes [32]. Yet, another study by Shinn
et al. in 2011 [33] explored possible associations between genet-
ic polymorphisms in nine exons of gene encoding the 5-HTR3B
receptor in relation to the occurrence of post-operative nausea
and vomiting. They failed to ﬁnd the similar association as was
earlier seen by Tremblay et al. However they found that 201–
202 del of CA inﬂuenced the post-operative nausea and vom-
iting incidence [32]. Thus so far only two studies have been
conducted in Caucasians one revealing an association between
AAG deletion variant of 5HT3B receptor gene and antiemetic
response to 5-HT3RAs [34] and the other one not going in fa-
vour of it [35]. Among the very few studies from Asia, one is
conducted in Japanese and one on Indonesians [34,35]. Tanaka
et al. were able to show that deletion AAG at position 100–102
of the 5-HT3B receptor was signiﬁcantly associated with the
failure of response to 5-HT3B receptor antagonists in CINV
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AAG was studied. This effect of deletion AAG or its haplo-
types needs to be explored in different populations in relation
to unresponsiveness to 5HT3RAs. Pharmacogenetic ﬁndings
cannot always be simply translated among ethnicities due to
differences in allele frequencies, haplotypes and gene function-
ality. So far to best of our knowledge this area of research has
remained unfocused in our part of the world. This area of the
world has yet not given any reports in this regard.
There is limited information available so far providing data
regarding ABCB1 and 5-HT3B gene frequency status and allele
frequency from different regions of the world. Studies have
been carried out in some populations which have shown racial
differences in these allelic frequencies. Therefore, it would be
of great interest to determine the clinically signiﬁcant SNPs
in ABCB1 and 5-HT3B genes in our population too and to
establish any importance of these as potential determinant of
altered drug responses. There is a possibility that the popula-
tion in different geographic regions of the world may have
widely varying genetic allele frequencies for clinically relevant
SNPs. By identifying the allelic frequency of common alleles in
different ethnic populations, a comprehensive dosing model
that is applicable regardless of ethnicity can be developed.
Conﬁrmation of a predictive role of these SNPs could contrib-
ute to future individualized treatment for post-operative nau-
sea and vomiting patients and thereby a better treatment
outcome and long term economic beneﬁt. This will help in
drafting clinical guidelines for 5HT3RAs prescription leading
to enhanced efﬁcacy and safety of 5HT3RAs.
World over genetic variations are under investigation. It is
the utmost obligation on our part to consider and explore the
genetic variations in our area too. The information gained
through such studies will help in drafting guidelines for newer
researchers in the ﬁeld of pharmacogenetics. We will add not
only to the knowledge of aetiology of post-operative nausea
and vomiting which is considered to be multifactorial, but
we may be able to explore the genetic basis for the inter indi-
vidual variations to the study drug. This recognition of the
relation between genotype and drug response is highly ex-
pected to affect the medical practice.References
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